Neurobiological Technologies, Inc.
NTII · OTC
9/30/2009 | 6/30/2009 | 3/31/2009 | 12/31/2008 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -0.00 | 0.11 | -0.00 |
| FCF Yield | 9.72% | -28.00% | -18.75% | -59.26% |
| EV / EBITDA | 2.84 | 0.67 | -46.46 | -0.18 |
| Quality | ||||
| ROIC | 17.37% | 0.00% | 0.00% | 0.00% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.44 | -0.36 | 7.85 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.72% | 14.24% | -8.96% | -7.01% |
| Free Cash Flow Growth | 146.30% | -50.47% | 31.62% | -64.10% |
| Safety | ||||
| Net Debt / EBITDA | -1.86 | -0.56 | 23.20 | 0.86 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 44.81 | 1.02 | 6.84 | 5.16 |